ERA4TB, or European Accelerator of Tuberculosis Regime, is a public-private initiative devoted to accelerate the development of new treatmen regimens for Tuberculosis. This project integrates more than thirty organizations from the European Union and the United States among which are the main global actors in the fight against tuberculosis infection.

ERA4TB is expected to revolutionize the way in which tuberculosis treatments are developed thanks to its parallelized, multi-entry pipeline structure, analogue to a production line. This structure will enable to systematically investigate the efficacy of several drug candidates and combinations simultaneously while allowing new molecules to enter the project pipeline at the research stage corresponding to the degree of knowledge on said candidate drugs gathered before the project.

With this approach, the ERA4TB consortium expects to reduce the time required for the development of new tuberculosis treatment regimens by up to a quarter.

ERA4TB has started on 2020 and will last six years, at the end of which, the consortium expects to have developed at least two or more new combination regimens with treatment-shortening potential ready for Phase II clinical evaluation. The partners intend to maintain the ERA4TB platform active beyond the project official duration.

To read more about ERA4TB, visit their website at https://era4tb.org/